(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 13.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Adaptive Biotechnologies's revenue in 2026 is $295,407,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $46,785,777,113, with the lowest ADPT revenue forecast at $44,324,294,364, and the highest ADPT revenue forecast at $48,733,517,364. On average, 10 Wall Street analysts forecast ADPT's revenue for 2027 to be $57,436,731,401, with the lowest ADPT revenue forecast at $54,549,530,569, and the highest ADPT revenue forecast at $60,026,249,664.
In 2028, ADPT is forecast to generate $70,033,825,495 in revenue, with the lowest revenue forecast at $63,625,648,040 and the highest revenue forecast at $75,000,002,979.